Efficacy and safety of ceforanide in the treatment of childhood infections.
Fifty-seven children, ages 1 month to 17 years, were treated with parenteral ceforanide. Most patients received 20 mg/kg of the drug intramuscularly every 12 hours. The mean duration of ceforanide therapy was 6.3 days (range, 3 to 14 days). Because ceforanide has a relatively long half-life of 1.94 +/- 0.43 hours (range, 1.1 to 3.3 hours), suprainhibitory plasma concentrations against most pathogens recovered from the study patients were maintained for 8 to 12 hours after a dose. Ceforanide diffused well into abscess cavities and joint fluid. Initial clinical response was satisfactory in all patients; however, one patient with Haemophilus influenzae type b bacteremia had relapse of bacteremia one week after ceforanide therapy. Ceforanide was well-tolerated with minimal pain at the site of intramuscular injections. Other side effects were minor and transient.
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy*; D002435:Cefamandole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male
D002435:Cefamandole; C012653:ceforanide